Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989–2015

Leukemia ◽  
2017 ◽  
Vol 31 (8) ◽  
pp. 1822-1825 ◽  
Author(s):  
M van der Meulen ◽  
A G Dinmohamed ◽  
O Visser ◽  
J K Doorduijn ◽  
J E C Bromberg
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
The Netherlands ◽  
Central Nervous System Lymphoma ◽  
Primary Treatment ◽  
Population Based ◽  
Population Based Study

scholarly journals Conditional relative survival in primary central nervous system lymphoma: a population-based study in the Netherlands

2020 ◽  
Vol 2 (1) ◽  
Author(s):  
Avinash G Dinmohamed ◽  
Matthijs van der Meulen ◽  
Otto Visser ◽  
Jeanette K Doorduijn ◽  
Jacoline E C Bromberg
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
The Netherlands ◽  
Central Nervous System Lymphoma ◽  
Relative Survival ◽  
Population Based ◽  
Population Based Study

scholarly journals OS10.3 Primary therapy and survival in over 70-year-old patients with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands

2019 ◽  
Vol 21 (Supplement_3) ◽  
pp. iii21-iii21
Author(s):  
M van der Meulen ◽  
J E C Bromberg ◽  
O Visser ◽  
J K Doorduijn ◽  
A G Dinmohamed
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
The Netherlands ◽  
Elderly Patients ◽  
Age Groups ◽  
Central Nervous System Lymphoma ◽  
Population Based ◽  
Primary Therapy ◽  
Age Group ◽  
Population Based Study

Abstract BACKGROUND Elderly patients with primary central nervous system lymphoma (PCNSL) have a poor prognosis. In this contemporary, nationwide, population-based study, we assessed the contribution of primary therapy on overall survival (OS) among elderly PCNSL patients in the Netherlands. METHODS All patients aged ≥ 70 years with cytologically and/or histologically proven PCNSL diagnosed between 2014–2016 were selected from the nationwide Netherlands Cancer Registry. Univariable analysis of OS was performed with the log-rank test. Multivariable Cox regression was applied to assess factors associated with OS, with adjustment for age (71–74, 75–79 and ≥80 years), sex, prior malignancy, primary therapy (no therapy, radiotherapy [RT] only, chemotherapy [CT]), and rituximab treatment. RESULTS Overall, 109 patients were registered; 39%, 39%, and 22% were aged 71–74, 75–79 and ≥80 years, respectively. Most patients received CT (45%), followed by no therapy (33%) and RT only (22%). With increasing age, the application of CT decreased (60%, 43%, and 24%), and RT only increased (10%, 26%, 26%) in the three age groups. CT consisted of methotrexate (MTX)-based or MTX only regimens in 98%. In patients treated with CT, Rituximab was added in 31%. During follow-up, 89 patients (82%) died. Median OS was 5.3 months (95% confidence interval [CI], 3.3–7.8), no difference was observed in median OS across the three age groups (6.8, 4.4, and 4.6 months, respectively; P=0.348). However, in the groups no therapy, RT only, and CT, median OS (95% CI) was 1.3 (1.0–2.0), 6.5 (4.4–12.5), and 20.3 (8.6–41.4) months (P<0.001), respectively. Moreover, 2 year OS (95%CI) was 49% (34–62) in patients treated with chemotherapy compared with 17% (5–34) in patients treated with RT. Median OS (95% CI) was 20.3 (8.6–41.4) in recipients of MTX-based regimens and 5.0 (2.4-not reached) months in recipients MTX only (P=0.185). In multivariable analysis, treatment with CT or RT was the only factor associated with OS: age group and the addition of Rituximab were not associated with OS. CONCLUSION In this contemporary population-based study, OS remained poor among patients with PCNSL aged over 70 years, irrespective of age group. Clinical condition likely influenced therapy choices but in those judged fit enough to receive CT, almost 50% survived 2 years. Therefore, future prospective intervention studies are warranted to assess which group of elderly patients benefit from CT or less intensive approaches.

scholarly journals Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France

Blood ◽  
2014 ◽  
Vol 124 (22) ◽  
pp. 3308-3315 ◽  
Author(s):  
Guillaume Moulis ◽  
Aurore Palmaro ◽  
Jean-Louis Montastruc ◽  
Bertrand Godeau ◽  
Maryse Lapeyre-Mestre ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Immune Thrombocytopenia ◽  
Population Based ◽  
Population Based Study ◽  
Regional Variations ◽  
Key Points ◽  
Central Nervous System Bleeding

Key Points Incidence of ITP was 2.9/100 000 person-years with age, seasonal, and regional variations; in adults, 18% were secondary. Severe (gastrointestinal or central nervous system) bleeding at ITP onset was rare (<1%); the risk increased with age.

scholarly journals Central Nervous System Metastases of Cutaneous Malignant Melanoma: A Population-based Study

1998 ◽  
Vol 37 (5) ◽  
pp. 463-470 ◽  
Author(s):  
Gabriella Cohn-Cedermark ◽  
Eva Månsson-Brahme ◽  
Lars Erik Rutqvist ◽  
Olle Larsson ◽  
Hemming Johansson ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Malignant Melanoma ◽  
Population Based ◽  
Cutaneous Malignant Melanoma ◽  
Population Based Study ◽  
Central Nervous System Metastases

scholarly journals Trends in incidence, primary treatment and survival in chronic myelomonocytic leukaemia: a population-based study of 1359 patients diagnosed in the Netherlands from 1989 to 2012

2015 ◽  
Vol 171 (3) ◽  
pp. 436-439 ◽  
Author(s):  
Avinash G. Dinmohamed ◽  
Mirian Brink ◽  
Otto Visser ◽  
Pieter Sonneveld ◽  
Arjan A. van de Loosdrecht ◽  
...  
Keyword(s):  
The Netherlands ◽  
Primary Treatment ◽  
Population Based ◽  
Population Based Study ◽  
Chronic Myelomonocytic Leukaemia
Sign in / Sign up

Export Citation Format

Share Document